Compare Lufax Holding Ltd (LU) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lufax Holding Ltd vs GeneDx Holdings Corp — how do they compare? Lufax Holding Ltd trades at $1.4 (market cap $2.41B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Lufax Holding Ltd is the larger of the two by market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Lufax Holding Ltd nearer its low. Which is the better fit depends on your goals.
| LU | WGS | |
|---|---|---|
Market Cap | $2.41B | $1.80B |
Sector | Technology | Technology |
52-Week High | $4.40 | $167.51 |
52-Week Low | $1.23 | $34.51 |
Enterprise Value | — | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LU trades at $1.36, down 2.16% today. The stock shows a mixed technical picture with a neutral overall signal and bearish moving averages. Fundamentally, the company reported a net loss of $2.1B on $23.1B revenue for 2025, with negative profit margins and returns. Analyst consensus is bullish with 61.5% buy ratings, but sentiment is clouded by multiple class-action lawsuits announced in May 2026 alleging securities fraud.
The outlook is cautious. While low valuation ratios (P/S 0.35, P/B 0.1) and analyst support suggest potential upside, persistent losses and significant legal overhangs pose substantial risks. Investor focus remains on the company's ability to return to profitability amid these challenges.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% amid a bearish technical signal and negative profitability. Recent earnings showed a Q1 2026 miss after two prior beats, with revenue growth but widening losses projected for 2026. The stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentations, with a deadline of August 3, 2026.
Despite a high analyst buy consensus (90.9%) and a $75.40 price target implying 24% upside, risks are elevated due to litigation, negative margins, and a high EV/EBITDA of 161.17. The upcoming Q2 2026 results on August 3 will be critical for investor confidence, but the legal overhang and fundamental challenges suggest cautious near-term outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
